M. Simmons

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).

N. Schultz, C. Chong, D. Solit, 2019, Journal of Clinical Oncology.

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.

B. Taylor, N. Schultz, D. Solit, 2020, The Lancet. Oncology.

Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer.

N. Schultz, D. Solit, W. Chatila, 2021 .

First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.

M. Berger, Laura H. Tang, D. Solit, 2023, The Lancet. Oncology.

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

N. Schultz, D. Solit, U. Bhanot, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.